Drugs Made in America Acquisition II Corp., a special purpose acquisition company, announced that starting December 3, 2025, investors who purchased units in its initial public offering can now separately trade the company's ordinary shares and rights on the Nasdaq Global Market. The ordinary shares will trade under the symbol "DMII" and the rights under "DMIIR." Units that remain combined will continue to trade under "DMIIU." Investors wishing to separate their units must coordinate with their brokers and the company's transfer agent, Continental Stock Transfer & Trust Company.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Drugs Made in America Acquisition II Corp. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9596034-en) on December 03, 2025, and is solely responsible for the information contained therein.